FDA to review Sanofi and Regeneron Biologics License Application for sarilumab
Sanofi and Regeneron Pharmaceuticals Inc. announced last week that the U.S. Food and Drug Administration (FDA) will review their Biologics License Application for sarilumab, an antibody that will help treat patients with moderate-to-severe rheumatoid arthritis. Read More »